Cargando…

Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer

SIMPLE SUMMARY: Bladder cancer (BCa) is one of the most common cancer types worldwide and is characterized by a high rate of recurrence. Previous studies have demonstrated that plasminogen activator inhibitor-1 (PAI1) plays an important role in bladder cancer development. The aim of our retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murakami, Kaoru, Furuya, Hideki, Hokutan, Kanani, Goodison, Steve, Pagano, Ian, Chen, Runpu, Shen, Cheng-Huang, Chan, Michael W. Y., Ng, Chi Fai, Kobayashi, Takashi, Ogawa, Osamu, Miyake, Makito, Thornquist, Mark, Shimizu, Yoshiko, Hayashi, Kazukuni, Wang, Zhangwei, Yu, Herbert, Rosser, Charles J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003630/ https://www.ncbi.nlm.nih.gov/pubmed/36902377 http://dx.doi.org/10.3390/ijms24054943

Ejemplares similares

Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2020)

PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity
por: Furuya, Hideki, et al.
Publicado: (2022)

Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation
por: Peres, Rafael, et al.
Publicado: (2016)

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients
por: Chan, Owen T.M., et al.
Publicado: (2017)

Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth
por: Miyake, Makito, et al.
Publicado: (2019)

Influencing Factors on the Oncuria™ Urinalysis Assay: An Experimental Model
por: Murakami, Kaoru, et al.
Publicado: (2021)

A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort
por: Goodison, Steve, et al.
Publicado: (2016)

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study
por: Murakami, Kaoru, et al.
Publicado: (2022)

A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome
por: Chen, Runpu, et al.
Publicado: (2022)

A multiplex immunoassay for the non-invasive detection of bladder cancer
por: Shimizu, Yoshiko, et al.
Publicado: (2016)

Diagnostic performance of Oncuria™, a urinalysis test for bladder cancer
por: Hirasawa, Yosuke, et al.
Publicado: (2021)

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2019)

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
por: Zhang, Ge, et al.
Publicado: (2014)

Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors
por: Zhang, Ge, et al.
Publicado: (2014)

Simultaneous multi-analyte urinary protein assay for bladder cancer detection
por: Rosser, Charles J, et al.
Publicado: (2014)

Prognostic Significance of Lymphocyte Infiltration and a Stromal Immunostaining of a Bladder Cancer Associated Diagnostic Panel in Urothelial Carcinoma
por: Furuya, Hideki, et al.
Publicado: (2019)

Clinical Utility of Oncuria™, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancer—A Pilot Study
por: Murakami, Kaoru, et al.
Publicado: (2022)

CXCL1 is elevated in the urine of bladder cancer patients
por: Burnier, Andre, et al.
Publicado: (2015)

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
por: Miyake, Makito, et al.
Publicado: (2013)

Influencing factors on the NMP-22 urine assay: an experimental model
por: Miyake, Makito, et al.
Publicado: (2012)

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer
por: Miyake, Makito, et al.
Publicado: (2014)

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer
por: Masuda, Norihiko, et al.
Publicado: (2018)

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers
por: Miyake, Makito, et al.
Publicado: (2013)

Identifying Significantly Perturbed Subnetworks in Cancer Using Multiple Protein–Protein Interaction Networks
por: Yang, Le, et al.
Publicado: (2023)

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection
por: Miyake, Makito, et al.
Publicado: (2013)

Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms
por: Furuya, Hideki, et al.
Publicado: (2023)

Computational approach for deriving cancer progression roadmaps from static sample data
por: Sun, Yijun, et al.
Publicado: (2017)

TFG-maintaining stability of overlooked FANCD2 confers early DNA-damage response
por: Ma, Chi, et al.
Publicado: (2020)

Radiosensitization in prostate cancer: mechanisms and targets
por: Palacios, Diego A, et al.
Publicado: (2013)

El País.
Publicado: (1983)

País portátil
por: González León, Adriano
Publicado: (1969)

País : antología 1955-1970 /
por: Otero, Blas de
Publicado: (1974)

Sphingosine kinase 1 expression enhances colon tumor growth
por: Furuya, Hideki, et al.
Publicado: (2017)

Sphingosine kinase 1 mediates head & neck squamous cell carcinoma invasion through sphingosine 1-phosphate receptor 1
por: Tamashiro, Paulette M, et al.
Publicado: (2014)

México, país de ideas, país de novelas : una sociología de la literatura mexicana /
por: Sefchovich, Sara
Publicado: (1987)

Focal cryosurgical ablation of the prostate: a single institute’s perspective
por: Hale, Zachary, et al.
Publicado: (2013)

Inhibitory DAMPs in immunogenic cell death and its clinical implications
por: Hayashi, Kazukuni, et al.
Publicado: (2021)

Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
por: Nikolos, Fotis, et al.
Publicado: (2022)

Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
por: Gomes-Giacoia, Evan, et al.
Publicado: (2014)

Un país feliz /
por: Vilalta, Maruxa
Publicado: (1965)

Cannot write session to /tmp/vufind_sessions/sess_4b3a7omkf6lqrn5aqkvuhmt22a